Spots Global Cancer Trial Database for Japanese Phase 1 Study to Evaluate Tolerated Dose, Safety, and Efficacy of Pomalidomide in Patients With Refractory or Relapsed and Refractory Multiple Myeloma
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Japanese Phase 1 Study to Evaluate Tolerated Dose, Safety, and Efficacy of Pomalidomide in Patients With Refractory or Relapsed and Refractory Multiple Myeloma
Official Title: A Phase 1, Multicenter, Open-label, Dose-escalation Study in Japan to Determine the Tolerated Dose and to Evaluate the Safety, Efficacy, and Pharmacokinetics of Pomalidomide Alone or in Combination With Dexamethasone in Patients With Refractory or Relapsed and Refractory Multiple Myeloma
Study ID: NCT01568294
Conditions
Interventions
Study Description
Brief Summary: The purpose of this study is to determine the tolerated dose of pomalidomide and also to evaluate the pharmacokinetics, safety and efficacy of pomalidomide in patients with refractory or relapsed and refractory multiple myeloma.
Detailed Description:
Keywords
Eligibility
Minimum Age: 20 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Nagoya City University Hospital, Nagoya, Aichi, Japan
Tokai University Hospital, Isehara, Kanagawa, Japan
Saitama Medical Center, Saitama Medical University, Kawagoe, Saitama, Japan
National Cancer Center Hospital, Tyuuou, Tokyo, Japan
Kyusyu University Hospital, Fukuoka, , Japan
Kameda General Hospital, Kamogawa, , Japan
Niigata Cancer Center Hospital, Niigata, , Japan
Okayama Medical Center, Okayama, , Japan
Contact Details
Name: Toru Sasaki
Affiliation: Celgene K.K
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
